Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 436,621
  • Shares Outstanding, K 100,434
  • Annual Sales, $ 41,288 K
  • Annual Income, $ -37,923 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 24.19
  • Price/Cash Flow N/A
  • Price/Book 3.50
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.03 on 11/10/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
680.000 unch
on 02/24/22
775.000 -12.26%
on 02/04/22
-95.000 (-12.26%)
since 01/24/22
3-Month
680.000 unch
on 02/24/22
800.000 -15.00%
on 11/30/21
-120.000 (-15.00%)
since 11/24/21
52-Week
680.000 unch
on 02/24/22
1,025.000 -33.66%
on 10/05/21
-270.000 (-28.42%)
since 02/24/21
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics GlobeNewswire - Wed Nov 13, 7:05AM CST

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance GlobeNewswire - Wed Nov 6, 3:05PM CST

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte to Participate in Two Upcoming Investor Conferences GlobeNewswire - Thu Oct 31, 7:05AM CDT

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Appoints Cynthia Collins to its Board of Directors GlobeNewswire - Tue Oct 15, 7:05AM CDT

PSTX : 2.67 (-3.26%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
CERT : 9.99 (+0.30%)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 GlobeNewswire - Fri Oct 11, 7:05AM CDT

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer GlobeNewswire - Thu Oct 10, 7:05AM CDT

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results Globe Newswire - Wed Aug 10, 2022

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022 Globe Newswire - Fri Jul 15, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Fri May 13, 2022

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte Reports First Quarter Financial Results Globe Newswire - Mon May 9, 2022

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 680.000
2nd Resistance Point 680.000
1st Resistance Point 680.000
Last Price 680.000
1st Support Level 680.000
2nd Support Level 680.000
3rd Support Level 680.000

See More

52-Week High 1,025.000
Fibonacci 61.8% 893.210
Fibonacci 50% 852.500
Fibonacci 38.2% 811.790
Last Price 680.000
52-Week Low 680.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot